Audit: QRS - Ibogaine for Health & Longevity

Audit conducted on 30/09/2026 03:07 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	87
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol, time-to-effect, gate, tier, marker and cadence content all trace to ER text (e.g., Therapeutic Protocol lines 367-375, Practical Considerations line 405, Monitoring lines 424-448).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	ER cautious phrasing kept, e.g., “No established target” for CYP2D6 genotype and symptom scales; tier placement mirrors ER.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening found; “Typically half or less of the standard dose” and contraindication thresholds match ER wording.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	QT-prolonging drugs are labelled “Absolute contraindication” in the ER (line 323), so surfacing them as a Contraindication is consistent; no modifying factor relabelled.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only “Stanford/Ambio” appears, taken from the ER protocol label (line 367); no PMIDs, NCT IDs or new brand names.
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms that remain (QTc, CYP2D6, NYHA, Child-Pugh) are decision-gate thresholds or ER labels; lede is plain language.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Lede closes with “No study has tested it for healthy aging”, reflecting the ER’s audience framing (lines 163, 473).
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Route stated as “oral” / “intravenous”; no consumer-grade phrasing found.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All <span data-qrs-var="NAME">...</span> from the [qrs_template] are present in the the QRS.	🟢	All template spans present; marker_# and qualitative_item_# expanded to 10 and 7 instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against template shows changes only inside variable spans, metadata and title; website spans and footer untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢	Empty ER tiers (Benefits High, Risks Medium) are hidden per 12.5/13.5; no other empty ER section is surfaced.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Magnesium-ibogaine (Stanford/Ambio)”, “Single ‘flood dose’ detoxification”, “Genetic polymorphisms” and gate item labels are ER bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Sections are condensed relative to the ER; no content is extended beyond the template’s single-sheet structure.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration is quoted (“00:00”), which contains a colon and requires quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.9.29 matches QRS.md version.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	09/30/2026 matches qrs_creation_date 2026-0930-0237.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens with “a mind-altering plant compound from Africa used in clinics for addiction and brain injury”.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	69 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each fact maps to ER Conclusion lines 469-473 and Therapeutic Protocol line 365.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight “Populations who should avoid” bullets plus the absolute contraindication (QT-prolonging drugs) are listed.
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	NYHA class II-IV, Child-Pugh class B or C, QTc and electrolyte thresholds and 6-month window preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation in contraindication items.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated; ER identifies multiple populations to avoid.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention -->	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	QT-prolonging drugs are excluded from Key Interactions because they are listed as a Contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved (shortened to drug names) for every ER interaction bullet.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation in interaction items.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated; ER identifies numerous interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no interaction that changes how the intervention is used -->	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides more than three actionable implementation aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Covers the three ER time-to-effect statements (hours, days, one month to a year; ER line 405).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Medium-tier benefit (reduced substance use) is first, followed by the two Low-tier benefits.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides three distinct time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high span set to display: none; ER has no High benefit.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_medium span set to display: none; ER has no Medium risk.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table biomarkers listed, plus the pregnancy test named in the ER monitoring text (line 424).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Cadence mirrors ER line 426.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers (lines 442-448) listed.

Issues 30/09/2026 03:07

Pass rate 100.00%. No issues found.

Issues 30/09/2026 03:04

1. 1.3 — At-a-glance strengthens evidence claim: Line 433 states ibogaine “has shown quick relief from opioid withdrawal, lower drug use, and better mood and thinking”, whereas the ER Conclusion describes these only as “signals” whose drug-attributable share “remains unknown”.

Fixes 30/09/2026 03:04

1. 1.3 — At-a-glance claim softened: Changed “has shown quick relief” to “is linked to quick relief” in the at-a-glance lede so it no longer asserts an established effect beyond the ER’s “signals” wording (69 words).

Issues 30/09/2026 03:01

1. 4.5 — Gate items exceed page budget: The Contraindications and Key Interactions gates (lines 542-567) keep long, uncondensed parenthetical example lists (e.g., “SSRIs such as sertraline, SNRIs such as venlafaxine, MAO inhibitors such as phenelzine”), which together with the 10-row Monitoring table and 7 qualitative items push the sheet beyond one A4 page.

Fixes 30/09/2026 03:01

1. 4.5 — Condensed gate example lists: In Key Interactions, trimmed the Serotonergic drugs list to “(sertraline, venlafaxine, phenelzine, tramadol)”, the Heart-rate and electrolyte-altering drugs list to “(metoprolol, verapamil, furosemide)”, and the additive-heart-effect supplements list to “(caffeine-based pre-exercise stimulants, yohimbine, synephrine, senna, dandelion)”, keeping every named example.

Issues 30/09/2026 02:58

1. 9.5 — Named example drugs dropped: The ER example drugs were removed entirely from three Key Interactions items: serotonergic drugs (QRS line 560, missing sertraline, venlafaxine, phenelzine), heart-rate and electrolyte-altering drugs (line 561, missing metoprolol, verapamil, furosemide) and laxative or diuretic herbs (line 566, missing senna, dandelion).

Fixes 30/09/2026 02:58

1. 9.5 — Restored named example drugs: Added the ER example drugs back into three Key Interactions items: sertraline, venlafaxine and phenelzine (serotonergic drugs), metoprolol, verapamil and furosemide (heart-rate and electrolyte-altering drugs), and senna and dandelion (laxative or diuretic herbs).

Issues 30/09/2026 02:56

1. 14.2 — Pregnancy test marker missing: The ER Monitoring section (line 424) lists “a pregnancy test where relevant” among baseline tests, but the QRS Monitoring table (lines 605-705) has no row for it.

Fixes 30/09/2026 02:56

1. 14.2 — Pregnancy test marker added: Added a Monitoring row “Pregnancy test (where relevant)” with target “Negative” and why “Pregnancy excludes treatment” as marker_9, renumbering Symptom scales to marker_10.

Issues 30/09/2026 02:51

1. 4.5 — Exceeds one A4 page: The sheet would render at about 1.8 A4 pages; the Key Interactions gate (lines 557-568) keeps long example lists (e.g. heart-rate/electrolyte drugs, heart-effect supplements), and time_3_sub (line 511) and action_1_sub (line 450) are verbose rather than condensed to the one-page budget.

Fixes 30/09/2026 02:51

1. 4.5 — Condensed toward one-page budget: Cut the Key Interactions example lists down to class names for serotonergic drugs (“SSRIs, SNRIs, MAO inhibitors, tramadol”) and heart-rate/electrolyte drugs (“beta-blockers, calcium channel blockers, diuretics”), dropped “such as senna and dandelion” from the heart-effect supplements item, and shortened time_3_sub to “Large gains measured at one month in veterans with brain injury”. action_1_sub is unchanged.

Issues 30/09/2026 02:49

1. 2.7 — Unexpanded HCl abbreviation: action_2_value (line 458) reads “8–12 mg/kg ibogaine HCl, one oral dose”; the ER spells out “ibogaine hydrochloride (HCl)”, so the bare chemical abbreviation is unnecessary jargon on the sheet.

Fixes 30/09/2026 02:49

1. 2.7 — Unexpanded HCl abbreviation: Changed action_2_value from “8–12 mg/kg ibogaine HCl, one oral dose” to “8–12 mg/kg ibogaine hydrochloride, one oral dose”, matching the ER’s spelled-out term.

Issues 30/09/2026 02:46

1. 1.1 / 1.6 — Unsupported timing attribution: time_3_sub (line 511) “Seen in veterans with brain injury after magnesium-ibogaine” pairs the “Within days” onset with the veteran cohort, whereas the ER reports that cohort’s gains at one month and states the within-days timing only generically in Practical Considerations.
2. 4.3 — Abbreviated time-to-effect label: time_1_label (line 483) “Reduced substance use” abbreviates the ER heading “Reduced Substance Use After Treatment”.

Fixes 30/09/2026 02:46

1. 1.1 / 1.6 — Unsupported timing attribution: Replaced time_3_sub “Seen in veterans with brain injury after magnesium-ibogaine” with “In veterans with brain injury, large gains in mood and daily functioning were measured at one month”, matching the ER’s one-month measurement.
2. 4.3 — Abbreviated time-to-effect label: Changed time_1_label from “Reduced substance use” to the verbatim ER heading “Reduced substance use after treatment”.

Issues 30/09/2026 02:42

1. 1.1 — Unsupported single-session claim: In Time to effect, time_3_sub (line 511) reads “Reported after a single session”, which the ER does not state; the ER links mood and functional changes to veterans with brain injury after magnesium-ibogaine.

Fixes 30/09/2026 02:42

1. 1.1 — Unsupported single-session claim: Changed time_3_sub from “Reported after a single session” to “Seen in veterans with brain injury after magnesium-ibogaine”, matching the ER’s Expected Benefits wording.

Issues 30/09/2026 02:40

1. 1.3 — Dropped hedge in protocol: [action_3_value] “Half or less of the standard dose” (QRS line 469) omits the ER’s “typically” (ER line 375), strengthening a described practice into a flat rule.
2. 9.5 — Interaction qualifiers dropped: Serotonergic example drugs (sertraline, venlafaxine, phenelzine) and the drug classes beta-blockers, calcium channel blockers, diuretics and laxative or diuretic herbs from ER lines 326, 327 and 332 are missing from QRS lines 560, 561 and 566.
3. 11.4 — Duration shown as onset: [time_1_value] “Months” (QRS line 486) presents how long reduced substance use lasted as a time to effect; ER line 405 says reported benefits “have lasted one month to a year”.

Fixes 30/09/2026 02:40

1. 1.3 — Restored protocol dose hedge: Changed [action_3_value] from “Half or less of the standard dose” to “Typically half or less of the standard dose”, matching ER line 375.
2. 9.5 — Restored interaction qualifiers: Added the example drugs sertraline, venlafaxine and phenelzine to the serotonergic item, and the classes beta-blockers, calcium channel blockers, diuretics and laxative or diuretic herbs to the heart-rate and supplement items, per ER lines 326, 327 and 332.
3. 11.4 — Duration no longer shown as onset: Changed [time_1_value] from “Months” to “Lasting months” so it reflects the reported duration of benefit (ER line 405).